Growth factors and wound healing: Biochemical properties of growth factors and their receptors

doi:10.1016/S0002-9610(05)80797-4

The American Journal of Surgery

Volume 165, Issue 6, June 1993, Pages 728-737

https://doi.org/10.1016/S0002-9610(05)80797-4 Get rights and content

Wound healing is a complex biologic process that involves chemotaxis and division of cells, neovascularization, synthesis of extracellular matrix proteins, and remodeling of scar. Peptide growth factors have been shown to regulate many of these processes in vitro, leading to the hypothesis that peptide growth factors also regulate important phases of wound healing in vivo. Part I of this two-part series presents an overview of the biochemical properties of five families of peptide growth factors that are thought to be involved in wound healing: epidermal growth factor (EGF), transforming growth factor-β (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factor (IGF), and fibroblast growth factor (FGF).

References (76)

WingrenU et al.
Epidermal growth factor accelerates connective tissue wound healing in the perforated rat mesentery
J Surg Res
(1992)
DerynckR
Transforming growth factor alpha
Cell
(1988)
WongST et al.
The TGF-α precursor expressed on the cell surface binds to the EGF receptor on adjacent cells, leading to signal transduction
Cell
(1989)
MassagueJ
Transforming growth factor α: a model for membrane-anchored growth factors
J Biol Chem
(1990)
CarpenterG et al.
Epidermal growth factor
J Biol Chem
(1990)
GillGN et al.
Epidermal growth factor and its receptor
Mol Cell Endocrinol
(1987)
AharonovA et al.
Epidermal growth factor: relationship between receptor regulation and mitogensis in 3T3 cells
J Biol Chem
(1978)
SpaargarenM et al.
Antibody-induced dimerization activates the epidermal growth factor receptor tyrosine kinase
J Biol Chem
(1991)
BerticsPJ et al.
Alteration of epidermal growth factor receptor activity by mutation of its primary carboxyl-terminal site of tyrosine self-phosphorylation
J Biol Chem
(1988)
WaltonGM et al.
Analysis of deletions of the carboxyl terminus of the epidermal growth factor receptor reveals self-phosphorylation at tyrosine 992 and enhanced in vivo tyrosine phosphorylation of cell substrates
J Biol Chem
(1990)

WangXF et al.

Expression cloning and characterization of the TGF-β type III receptor

Cell

(1991)

LinHY et al.

Expression cloning of the type II TGF-β receptor

Cell

(1992)

BaxterRC

The somatomedins: Insulin-like growth factors

Adv Clin Chem

(1986)

ShimasakiS et al.

Identification of five different insulin-like growth factor binding proteins (IGFBPs) from adult rat serum and molecular cloning of a novel IGFBP-5 in rat and human

J Biol Chem

(1991)

VaismanN et al.

Characterization of the receptors for vascular endothelial growth factor

J Biol Chem

(1990)

RobsonMC et al.

Platelet-derived growth factor BB for the treatment of chronic pressure ulcers

Lancet

(1992)

BellGI et al.

Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization

Nucleic Acids Res

(1986)

PesonenK et al.

Characterization of material with epidermal growth factor immunoreactivity in human serum and platelets

J Clin Endocrinol Metab

(1989)

FisherDA et al.

Metabolism and effects of epidermal growth factor and related growth factors in mammals

Endocr Rev

(1990)

BrownGL et al.

Enhancement of epidermal regeneration by biosynthetic epidermal growth factor

J Exp Med

(1986)

SchultzG et al.

EGF and TGF-α in wound healing and repair

J Cell Biochem

(1991)

NishidaT et al.

Fibronectin synthesis in by the rabbit cornea: effects of mouse epidermal growth factor and cyclic AMP analogs

Jpn J Ophthalmol

(1984)

O'DanielTG et al.

Epidermal growth factor binding and action on tympanic membranes

Ann Otol Rhinol Laryngol

(1990)

BrownGL et al.

Enhancement of wound healing by topical treament with epidermal growth factor

N Engl J Med

(1989)

BrownGL et al.

Stimulation of healing of chronic wounds by epidermal growth factor

Plast Reconstr Surg

(1991)

DanieleS et al.

The effect of the epidermal growth factor (EGF) on the corneal epithelium in humans

Graefes Arch Clin Exp Ophthalmol

(1979)

AnklesariaP et al.

Cell-cell adhesion mediated by binding of membraneanchored transforming growth factor α to epidermal growth factor receptors promotes cell proliferation

Proc Natl Acad Sci U S A

(1990)

BurgessAW

Epidermal growth factor and transforming growth factor α

Br Med Bull

(1989)

SchultzGS et al.

Epithelial wound healing enhanced by transforming growth factor α and vaccinia growth factor

Science

(1987)

WinklerME et al.

Epidermal growth factor and transforming growth factor α bind differently to the epidermal growth factor receptor

Biochemistry

(1989)

HigashiyamaS et al.

A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF

Science

(1991)

ShoyabM et al.

Amphiregulin: A bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7

Proc Natl Acad Sci USA

(1988)

ShoyabM et al.

Structure and function of human amphiregulin: a member of the epidermal growth factor family

Science

(1989)

CookPW et al.

A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin

Mol Cell Biol

(1991)

CarpenterG et al.

The epidermal growth factor family

ChenWS et al.

Requirement for intrisic protein tyrosine kinase in the immediate and late actions of the EGF receptor

Nature

(1987)

RiedelH et al.

A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor

Nature

(1986)

HaiglerHT et al.

Direct visualization of binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cell a-431

J Cell Biol

(1979)

Cited by (409)

Debridement Techniques and Non–Negative Pressure Wound Therapy Wound Management
2017, Veterinary Clinics of North America - Small Animal Practice
Dual-layered 3D nanofibrous matrix incorporated with dual drugs and their synergetic effect on accelerating wound healing through growth factor regulation
2017, Materials Science and Engineering C
The by-product of the slaughter house was utilized for the development of promising regenerative wound dressing material. Currently, dual-layered nanofibrous spongy scaffold was fabricated for tissue engineering applications. Herein, Keratin (K)-Fibrin (F)-Gelatin (G) 3D sponge loaded with Mupirocin (M) was fabricated with the naturally derived materials from bovine origin using freeze drying method. Moreover, poly(3-hydroxybutyric acid) (P) and Gelatin(G) solution loaded with Curcumin (C) were electrospun to get the dual drug loaded dual-layered nanofibrous spongy 3D scaffold (KFG:M-PG:C). The fabricated biomaterial was assisted with physical, biological and mechanical property. The in vitro cell viability and fluorescence staining of NIH 3T3 and HaCaT cells assist in cell adhesion and proliferation of the dual-layered scaffold. Moreover, in vivo assessment using silicone splint animal model was employed. The nanofibrous surface aids in the migration of fibroblast for the increased the collagen deposition and granulation tissue formation. Nonetheless, the 3D spongy surface promotes the gaseous exchange and absorption of exudates. The fabricated KFG:M-PG:C scaffold has the ability to produce perusable material that can integrate with the host tissue. Overall, the three dimensional (3D) dual-layered nanofibrous spongy scaffold with synergistic effect of dual drugs prevents from infection and facilitates as highly durable substrate in tissue engineering application.
Epidermal growth factor loaded heparin-based hydrogel sheet for skin wound healing
2016, Carbohydrate Polymers
A heparin-based hydrogel sheet composed of thiolated heparin and diacrylated poly (ethylene glycol) was prepared via photo polymerization and human epidermal growth factor (hEGF) were loaded into it for the purpose of wound healing. It showed a sustained release profile of hEGF in vitro. In order to evaluate its function on wound healing in vivo, full thickness wounds were created on the dorsal surface of mice. Application of hEGF loaded heparin-based hydrogel sheet accelerated the wound closure compared to the non-treated control group, hEGF solution, and hEGF loaded PEG hydrogel sheet. Histological and immunohistological examinations also demonstrated an advanced granulation tissue formation, capillary formation, and epithelialization in wounds treated by hEGF loaded heparin-based hydrogel compared to other groups, and no biocompatibility issue was observed. In conclusion, the delivery of hEGF using the heparin-based hydrogel could accelerate the skin wound healing process.
Fibroblast growth factors, Old kids on the new block
2016, Seminars in Cell and Developmental Biology
The fibroblast growth factors (FGFs) are a family of cell intrinsic regulatory peptides that control a broad spectrum of cellular activities. The family includes canonic FGFs that elicit their activities by activating the FGF receptor (FGFR) tyrosine kinase and non-canonic members that elicit their activities intracellularly and via FGFR-independent mechanisms. The FGF signaling axis is highly complex due to the existence of multiple isoforms of both ligands and receptors, as well as cofactors that include the chemically heterogeneous heparan sulfate (HS) cofactors, and in the case of endocrine FGFs, the Klotho coreceptors. Resident FGF signaling controls embryonic development, maintains tissue homeostasis, promotes wound healing and tissue regeneration, and regulates functions of multiple organs. However, ectopic or aberrant FGF signaling is a culprit for various diseases, including congenital birth defects, metabolic disorder, and cancer. The molecular mechanisms by which the specificity of FGF signaling is achieved remain incompletely understood. Since its application as a druggable target has been gradually recognized by pharmaceutical companies and translational researchers, understanding the determinants of FGF signaling specificity has become even more important in order to get into the position to selectively suppress a particular pathway without affecting others to minimize side effects.
Controlled co-immobilization of EGF and VEGF to optimize vascular cell survival
2016, Acta Biomaterialia
Growth factors (GFs) are potent signaling molecules that act in a coordinated manner in physiological processes such as tissue healing or angiogenesis. Co-immobilizing GFs on materials while preserving their bioactivity still represents a major challenge in the field of tissue regeneration and bioactive implants. In this study, we explore the potential of an oriented immobilization technique based on two high affinity peptides, namely the Ecoil and Kcoil, to allow for the simultaneous capture of the epidermal growth factor (EGF) and the vascular endothelial growth factor (VEGF) on a chondroitin sulfate coating. This glycosaminoglycan layer was selected as it promotes cell adhesion but reduces non-specific adsorption of plasma proteins. We demonstrate here that both Ecoil-tagged GFs can be successfully immobilized on chondroitin sulfate surfaces that had been pre-decorated with the Kcoil peptide. As shown by direct ELISA, changing the incubation concentration of the various GFs enabled to control their grafted amount. Moreover, cell survival studies with endothelial and smooth muscle cells confirmed that our oriented tethering strategy preserved GF bioactivity. Of salient interest, co-immobilizing EGF and VEGF led to better cell survival compared to each GF captured alone, suggesting a synergistic effect of these GFs. Altogether, these results demonstrate the potential of coiled-coil oriented GF tethering for the co-immobilization of macromolecules; it thus open the way to the generation of biomaterials surfaces with fine-tuned biological properties.
Growth factors are potent signaling molecules that act in a coordinated manner in physiological processes such as tissue healing or angiogenesis. Controlled coimmobilization of growth factors on biomaterials while preserving their bioactivity represents a major challenge in the field of tissue regeneration and bioactive implants. This study demonstrates the potential of an oriented immobilization technique based on two high affinity peptides to allow for the simultaneous capture of epidermal growth factor (EGF) and vascular endothelial growth factor (VEGF). Our system allowed an efficient control on growth factor immobilization by adjusting the incubation concentrations of EGF and VEGF. Of salient interest, co-immobilizing of specific ratios of EGF and VEGF demonstrated a synergistic effect on cell survival compared to each GF captured alone.
Hormonal manipulation with toremifene in sporadic desmoid-type fibromatosis
2015, European Journal of Cancer
Many patients affected by desmoid-type fibromatosis (DF) are treated with a course of hormonal therapy as front line. So far, tamoxifene has been the preferred choice. Toremifene is an anti-oestrogen agent, but possible further mechanisms of action in desmoids are related to its role in regulation of transforming growth factor-beta and β-catenin pathways.
We retrospectively reviewed all patients treated with toremifene between 2005 and 2012 at a reference institution. Indication to toremifene was radiologically progressive disease and/or symptomatic deterioration. Progression-free survival (PFS), clinical benefit (CB) and safety profile were analysed.
Forty-four patients were treated with toremifene 180 mg daily, 20 for radiological progression, 16 for pain and 8 for both. In 28 patients, toremifene was offered as front-line therapy, while in 11 after tamoxifen failure. PFS was 89.6% at 2 years. According to Response Evaluation Criteria in Solid Tumours, partial response, stable disease and disease progression were observed in 25%, 65% and 10% of the patients, respectively. Symptomatic relief was obtained in 75% of patients. Median time to response was 4 months. Overall CB was 86%. Adverse events G≥2 according to National Cancer Institute Common Toxicity Criteria were recorded in ten patients.
Present series provides evidence to make toremifene an option in patients with DF, even after failure on different hormonal agents. A prospective trial is ongoing to confirm these results.

View all citing articles on Scopus

^*: Supported in part by the U.S. Army Medical Research and Development Command under Contract No. DAMD17-91-C-1095 and by NIH Grant EY 05587.

¹: From the Department of Surgery University of Florida, Gainesville, Florida.

²: From the Department of Obstetrics and Gynecology, University of Florida, Gainesville, Florida.

View full text

Growth factors and wound healing: Biochemical properties of growth factors and their receptors*

J Surg Res

Cell

Cell

J Biol Chem

J Biol Chem

Mol Cell Endocrinol

J Biol Chem

J Biol Chem

J Biol Chem

J Biol Chem

Cell

Cell

Adv Clin Chem

J Biol Chem

J Biol Chem

Lancet

Human epidermal growth factor precursor: cDNA sequence, expression in vitro and gene organization

Nucleic Acids Res

Characterization of material with epidermal growth factor immunoreactivity in human serum and platelets

J Clin Endocrinol Metab

Metabolism and effects of epidermal growth factor and related growth factors in mammals

Endocr Rev

Enhancement of epidermal regeneration by biosynthetic epidermal growth factor

J Exp Med

EGF and TGF-α in wound healing and repair

J Cell Biochem

Fibronectin synthesis in by the rabbit cornea: effects of mouse epidermal growth factor and cyclic AMP analogs

Jpn J Ophthalmol

Epidermal growth factor binding and action on tympanic membranes

Ann Otol Rhinol Laryngol

Enhancement of wound healing by topical treament with epidermal growth factor

N Engl J Med

Stimulation of healing of chronic wounds by epidermal growth factor

Plast Reconstr Surg

The effect of the epidermal growth factor (EGF) on the corneal epithelium in humans

Graefes Arch Clin Exp Ophthalmol

Cell-cell adhesion mediated by binding of membraneanchored transforming growth factor α to epidermal growth factor receptors promotes cell proliferation

Proc Natl Acad Sci U S A

Epidermal growth factor and transforming growth factor α

Br Med Bull

Epithelial wound healing enhanced by transforming growth factor α and vaccinia growth factor

Science

Epidermal growth factor and transforming growth factor α bind differently to the epidermal growth factor receptor

Biochemistry

A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF

Science

Amphiregulin: A bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate 13-acetate-treated human breast adenocarcinoma cell line MCF-7

Proc Natl Acad Sci USA

Structure and function of human amphiregulin: a member of the epidermal growth factor family

Science

A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin

Mol Cell Biol

The epidermal growth factor family

Requirement for intrisic protein tyrosine kinase in the immediate and late actions of the EGF receptor

Nature

A chimaeric receptor allows insulin to stimulate tyrosine kinase activity of epidermal growth factor receptor

Nature

Direct visualization of binding and internalization of a ferritin conjugate of epidermal growth factor in human carcinoma cell a-431

J Cell Biol